Academic Journal
Q3Immunotherapy
About Immunotherapy
Immunotherapy is a scholarly journal published by Taylor and Francis Ltd.. SCImago 2025 lists it in Q3, with an SJR of 0.666 and H-index of 75.
Coverage: 2009-2026. Research categories: Immunology (Q3); Immunology and Allergy (Q3); Oncology (Q3).
Source-backed journal facts
Topics in published research
Cancer Immunotherapy and Biomarkers; Immunotherapy and Immune Responses; CAR-T cell therapy research; Immune Cell Function and Interaction; T-cell and B-cell Immunology; Allergic Rhinitis and Sensitization.
OpenAlex classifies topics from published works. These topics are not the publisher’s official aims and scope.
Source: OpenAlex source record. Retrieved 2026-10-03. Source record updated 2026-10-02. OpenAlex metrics are different from SCImago metrics and the Clarivate Journal Impact Factor.
Journal Metrics
Quartile, SJR and the listed SCImago H-index use the 2025 imported SCImago dataset. A quartile may vary by subject category. Values without a source or reporting year are unverified historical entries. Verify the current Journal Impact Factor with Clarivate or the publisher before using it.
Aims & Scope
The publisher’s official aims and scope have not yet been verified for this profile. Use the journal website to check subject fit and accepted article types before submitting.
Recent Research Articles
Latest publications matched automatically by ISSN.
Circulating and tumor microenvironment immunomarkers associate with immunotherapy efficacy in advanced bladder urothelial carcinoma: an exploratory multicenter study integrating genomic and immunophenotypic profiling
Sha Liu, Junjun Lu, Zhaojie Lyu, Zhengmao Lu et al.
2026-10-09 · DOI: 10.1080/1750743x.2026.2744059Liquid–liquid phase separation-related gene can predict prognosis and influence immune microenvironment in acute myeloid leukemia
Xiaoyue Ren, Lijie Zhang, Linli Zhou, Shuqi Zhao et al.
2026-10-08 · DOI: 10.1080/1750743x.2026.2743429Association of early dynamic changes in peripheral blood immune-inflammatory indices with subsequent acquired resistance to immune checkpoint inhibitors in advanced non-small cell lung cancer: a landmark analysis
Lin Song, Wanghui Lv, Qingbo Wang, Yan Luo et al.
2026-10-08 · DOI: 10.1080/1750743x.2026.2728538Efgartigimod in the treatment of severe Guillain–Barre syndrome with overlapping autoantibody syndrome: a case report and updated clinical review
Yueqi Wang, Siqi Wang, Huijuan Fan, Wenjun Sun et al.
2026-10-08 · DOI: 10.1080/1750743x.2026.2742742Cost-effectiveness analysis of penpulimab plus anlotinib versus sorafenib as first-line therapy for advanced hepatocellular carcinoma
Zhiwei Zheng, Lisheng Huang, Yuling Zhang, Huide Zhu et al.
2026-10-04 · DOI: 10.1080/1750743x.2026.2743426Real-world utilization of immune checkpoint inhibitors in medicare-eligible patients with triple-negative breast cancer in the United States
Xiaohan Hu, Amin Haiderali, Yezhou Sun, Wilbur Pan et al.
2026-10-04 · DOI: 10.1080/1750743x.2026.2742727Beyond PD-L1: emerging clinical and molecular biomarkers of response to immune checkpoint inhibitors in non-small cell lung cancer
Calogera Claudia Spagnolo, Irene Campo, Elena Fassi, Francesco Nucera et al.
2026-10-01 · DOI: 10.1080/1750743x.2026.2738337Addressing socioeconomic barriers to immunotherapy access for non-small cell lung cancer in Japan
Hiroe Suzuki-Chiba, Atsushi Miyawaki
2026-09-22 · DOI: 10.1080/1750743x.2026.2735709Efficacy and safety of chimeric antigen receptor T-cell therapy in primary central nervous system lymphoma: a systematic review and meta-analysis
Abdulrahman F. Al-Mashdali, Mujahid O. Abdelraof, Rasha Kaddoura, Azza M. Halfawi et al.
2026-09-16 · DOI: 10.1080/1750743x.2026.2722553From receptor biology to therapy: importance of different EGFR mutations in the development of targeted cancer therapies
U Krishnaja, Neethu J, Maitheli Sarkar, Krishnakumar N. Menon et al.
2026-09-15 · DOI: 10.1080/1750743x.2026.2728525In vivo CAR-T for solid tumors: facing all the challenges of ex vivo CAR-T and more
Yulong Xia, Jintian Song, Jiong Wu
2026-09-08 · DOI: 10.1080/1750743x.2026.2728543Bromodomain inhibitors in autoimmune diseases
Marcin Szczepanik, Wojciech Pociej, Joanna Kulpa, Jakub Senko et al.
2026-09-06 · DOI: 10.1080/1750743x.2026.2728534Cancer vaccines as targeted therapies: translational advances and challenges
Zahra Shafaghat, Maryam Sadri, Mona Roozbehani, Fatemeh Kheiri et al.
2026-09-05 · DOI: 10.1080/1750743x.2026.2728542Prognostic factors in avelumab maintenance therapy for metastatic urothelial carcinoma
Caner Kapar, Oğuzcan Özkan, Eda Eylemer Mocan, Sendag Yaslikaya et al.
2026-09-02 · DOI: 10.1080/1750743x.2026.2722548Efficacy of PARP inhibitor and immune checkpoint inhibitor combination therapy in PD-L1–negative cancers: a systematic review and meta-analysis
Susu Zhou, Vishw Patel, Noriko Kishi, Komal Akhtar et al.
2026-08-25 · DOI: 10.1080/1750743x.2026.2722581Low-dose interleukin-2 combined with thalidomide for a severe cutaneous immune-related adverse event associated with PD-1/CTLA-4 bispecific antibody therapy: a case report
Zhiqiang Li, Yufei Li, Yuhan Zhang, Qiuxia Ye et al.
2026-08-25 · DOI: 10.1080/1750743x.2026.2722556Injection-based safety of aqueous venom immunotherapy during venom extract shortage: impact of forced depot-to-aqueous switching
Gökten Bulut, Rukiye Demiralp, Şefika Karabaş, Fidan Coşkun et al.
2026-08-24 · DOI: 10.1080/1750743x.2026.2722552Lupus nephritis treatment: a comprehensive overview of recent meta-analyses and future directions
Feigao Li, Xizhe Liu, Bokun Chen, Menghao Li et al.
2026-07-03 · DOI: 10.1080/1750743x.2026.2705727Making dietary modification in the immunotherapy Era: from mechanistic evidence to practical implementation
Parham Habibzadeh, Drew Hurd, Diwakar Davar
2026-07-03 · DOI: 10.1080/1750743x.2026.2717073The role of artificial intelligence in predicting immunotherapy treatment outcomes based on gut microbiota composition in cancer patients: a meta-analysis
Leen Alhassan, Bassel Alrabadi, Suhel F. Batarseh, Yousef Alghzawi et al.
2026-07-03 · DOI: 10.1080/1750743x.2026.2717074Reviews
Community Reviews
Version History
October 4, 2026 at 9:10 pm
October 2, 2026